Abstract
Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis
Highlights
Provides a new hint to study the miRNA regulation of LCs and TRMs
We have previously shown that CD4 regulatory T (Treg)-cell numbers and suppressor function were enhanced in the peripheral blood of patients with rheumatoid arthritis (RA) who responded to anti-TNF antibody therapy in contrast to patients responding to the soluble TNF receptor etanercept.[3]
We investigated the role of p38 signaling in modulating monocyte membrane TNF expression by adalimumab because of its role in reverse signaling via membrane TNF.[6]
Summary
Provides a new hint to study the miRNA regulation of LCs and TRMs. Uncovering novel LC and TRM-associated miRNAs may potentially help in the development of specific miRNA therapies for some allergic diseases in the skin and lungs. There was a significant difference between responders and nonresponders (P 5 .016) with respect to the changes in Treg cells following in vitro stimulation with adalimumab (see Table E2 in this article’s Online Repository at www.jacionline.org).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
